MCID: GLC003
MIFTS: 55

Glucose Intolerance

Categories: Metabolic diseases

Aliases & Classifications for Glucose Intolerance

MalaCards integrated aliases for Glucose Intolerance:

Name: Glucose Intolerance 12 29 55 6 44 15
Impaired Glucose Tolerance 72
Malabsorption of Glucose 12
Glucose: Malabsorption 12
Glucose: Intolerance 12

Classifications:



External Ids:

Disease Ontology 12 DOID:10603
MeSH 44 D018149
NCIt 50 C34646
SNOMED-CT 68 9414007
ICD10 33 R73.03
UMLS 72 C0271650

Summaries for Glucose Intolerance

MalaCards based summary : Glucose Intolerance, also known as impaired glucose tolerance, is related to abdominal obesity-metabolic syndrome 1 and coronary heart disease 1. An important gene associated with Glucose Intolerance is MT-TL1 (Mitochondrially Encoded TRNA-Leu (UUA/G) 1), and among its related pathways/superpathways are Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. and Regulation of lipid metabolism Insulin signaling-generic cascades. The drugs Amiloride and Insulin glargine have been mentioned in the context of this disorder. Affiliated tissues include liver, ovary and testes, and related phenotypes are adipose tissue and endocrine/exocrine gland

Wikipedia : 75 Prediabetes is the precursor stage before diabetes mellitus in which not all of the symptoms required to... more...

Related Diseases for Glucose Intolerance

Diseases related to Glucose Intolerance via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 334)
# Related Disease Score Top Affiliating Genes
1 abdominal obesity-metabolic syndrome 1 32.3 SLC2A4 LEP INS ADIPOQ
2 coronary heart disease 1 31.3 RETN INS CRP ADIPOQ
3 fatty liver disease, nonalcoholic 1 31.2 RETN LEP INS GPT ADIPOQ
4 atherosclerosis susceptibility 31.1 INS CRP ADIPOQ
5 uremia 31.1 RETN LEP INS CRP
6 arteries, anomalies of 31.0 LEP INS CRP ADIPOQ
7 liver cirrhosis 30.9 RETN LEP GPT ADIPOQ
8 lipid metabolism disorder 30.9 RETN RBP4 LEP INS CRP ADIPOQ
9 hyperthyroidism 30.9 SHBG LEP INS GHRL
10 hypoglycemia 30.8 INSR INS GCK GCG
11 acute insulin response 30.8 INS GCG CRP
12 acromegaly 30.8 INS IGFBP1 IGF1 GHRL
13 hyperproinsulinemia 30.7 SHBG INS IGFBP1
14 vascular disease 30.7 RETN INS IGFBP1 CRP ADIPOQ
15 liver disease 30.7 LEPR LEP INS GPT ADIPOQ
16 fatty liver disease 30.6 LEPR LEP IRS1 INSR INS ADIPOQ
17 hypertension, essential 30.4 RETN LEP INSR INS ADRB3 ADIPOQ
18 sleep disorder 30.4 LEP INS CRP
19 insulinoma 30.4 INS GCK GCG
20 fetal macrosomia 30.4 LEP INSR INS IGF1
21 hyperinsulinemic hypoglycemia 30.4 INSR INS GCK
22 hyperandrogenism 30.3 SHBG INSR INS IGFBP1 IGF1
23 hypothyroidism 30.3 SHBG RETN LEP IGF1
24 apnea, obstructive sleep 30.3 LEP INS CRP ADIPOQ
25 polycystic ovary syndrome 30.3 SHBG LEP IRS1 INSR INS IGFBP1
26 hyperinsulinism 30.3 SHBG LEP INSR INS IGFBP1 IGF1
27 myocardial infarction 30.2 RETN INS GHRL CRP ADIPOQ
28 arteriosclerosis 30.1 INS CRP ADIPOQ
29 turner syndrome 30.1 SHBG IGFBP1 IGF1
30 anovulation 30.0 SHBG LEP INS IGF1 CRP
31 acanthosis nigricans 30.0 SHBG LEP INSR INS IGF1 ADIPOQ
32 gastrointestinal system disease 29.9 INS GHRL GCG CRP
33 eating disorder 29.9 LEPR LEP GHRL ADIPOQ
34 prediabetes syndrome 29.8 LEP INS GCG DPP4 CRP ADIPOQ
35 insulin-like growth factor i 29.8 SHBG LEP IRS1 INSR INS IGFBP1
36 gestational diabetes 29.6 SLC2A4 SHBG RETN RBP4 LEP IRS1
37 diabetes mellitus, insulin-dependent 29.6 INS IGFBP1 IGF1 GHRL GCK GCG
38 hyperglycemia 29.6 LEP IRS1 INSR INS IGF1 GCK
39 sleep apnea 29.5 LEPR LEP INS IGF1 GHRL CRP
40 maturity-onset diabetes of the young 29.2 IRS1 INS GCK GCG DPP4 CRP
41 pancreas disease 28.9 LEP INS IGF1 GCG DPP4 CRP
42 anorexia nervosa 28.8 RETN LEPR LEP IGFBP1 IGF1 GHRL
43 overnutrition 27.2 SLC2A4 SHBG RETN LEPR LEP IRS1
44 diabetes mellitus 27.0 SLC2A4 SHBG RETN LEP IRS1 INSR
45 diabetes mellitus, noninsulin-dependent 25.9 SLC2A4 SHBG RETN RBP4 LEPR LEP
46 body mass index quantitative trait locus 11 25.7 SLC2A4 SHBG RETN RBP4 LEPR LEP
47 lipodystrophy, familial partial, type 2 11.4
48 mental retardation, skeletal dysplasia, and abducens palsy 11.4
49 growth hormone insensitivity with immunodeficiency 11.2
50 aromatase deficiency 11.2

Graphical network of the top 20 diseases related to Glucose Intolerance:



Diseases related to Glucose Intolerance

Symptoms & Phenotypes for Glucose Intolerance

MGI Mouse Phenotypes related to Glucose Intolerance:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 adipose tissue MP:0005375 10.22 ADIPOQ ADRB3 GHRL IGF1 INS INSR
2 endocrine/exocrine gland MP:0005379 10.22 ADIPOQ ADRB3 DPP4 GCK GHRL IGF1
3 homeostasis/metabolism MP:0005376 10.2 ADIPOQ ADRB3 CRP DPP4 GCK GHRL
4 cardiovascular system MP:0005385 10.16 ADIPOQ CRP IGF1 INS INSR IRS1
5 growth/size/body region MP:0005378 10.11 ADIPOQ ADRB3 DPP4 GCK IGF1 INS
6 immune system MP:0005387 10 ADIPOQ CRP IGF1 IGFBP1 INS INSR
7 digestive/alimentary MP:0005381 9.98 GHRL INS INSR LEP LEPR RBP4
8 liver/biliary system MP:0005370 9.85 ADIPOQ GCK IGFBP1 INS INSR IRS1
9 muscle MP:0005369 9.61 ADIPOQ IGF1 INS INSR IRS1 LEP
10 renal/urinary system MP:0005367 9.23 ADIPOQ GCK IGF1 INS INSR LEP

Drugs & Therapeutics for Glucose Intolerance

Drugs for Glucose Intolerance (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 573)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Amiloride Approved Phase 4 2016-88-8, 2609-46-3 16231
2
Insulin glargine Approved Phase 4 160337-95-1
3
Rosiglitazone Approved, Investigational Phase 4 122320-73-4 77999
4
Nateglinide Approved, Investigational Phase 4 105816-04-4 60026
5
Pitavastatin Approved Phase 4 147511-69-1, 147526-32-7 5282452 6366718
6
Glyburide Approved Phase 4 10238-21-8 3488
7
Nebivolol Approved, Investigational Phase 4 152520-56-4, 118457-14-0, 99200-09-6 71301
8
Lisinopril Approved, Investigational Phase 4 83915-83-7, 76547-98-3 5362119
9
Linagliptin Approved Phase 4 668270-12-0 10096344
10
Trandolapril Approved Phase 4 87679-37-6 5484727
11
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
12
Clozapine Approved Phase 4 5786-21-0 2818
13
Tocopherol Approved, Investigational Phase 4 1406-66-2, 54-28-4 14986
14
Nitric Oxide Approved Phase 4 10102-43-9 145068
15
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
16
Iloperidone Approved Phase 4 133454-47-4 71360
17
Octreotide Approved, Investigational Phase 4 83150-76-9 383414 6400441
18
Hydroxychloroquine Approved Phase 4 118-42-3 3652
19
Norgestimate Approved, Investigational Phase 4 35189-28-7 6540478
20
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
21
Verapamil Approved Phase 4 52-53-9 2520
22
Chlorthalidone Approved Phase 4 77-36-1 2732
23
Budesonide Approved Phase 4 51333-22-3 63006 5281004
24
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
25
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
26
Ethanol Approved Phase 4 64-17-5 702
27
Liraglutide Approved Phase 4 204656-20-2 44147092
28
Bromocriptine Approved, Investigational Phase 4 25614-03-3 31101
29
Atorvastatin Approved Phase 4 134523-00-5 60823
30
Fluspirilene Approved, Investigational Phase 4 1841-19-6 3396
31
Glucagon Approved Phase 4 16941-32-5
32
Testosterone enanthate Approved Phase 4 315-37-7 9416
33
Methyltestosterone Approved Phase 4 58-18-4 6010
34
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0
35
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
36
Saxagliptin Approved Phase 4 361442-04-8 11243969
37
Sodium citrate Approved, Investigational Phase 4 68-04-2
38
Losartan Approved Phase 4 114798-26-4 3961
39
Enalapril Approved, Vet_approved Phase 4 75847-73-3 5362032 40466924
40
Enalaprilat Approved Phase 4 76420-72-9 6917719
41
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
42
Dextroamphetamine Approved, Illicit Phase 4 51-64-9 5826
43
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
44
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
45
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
46
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
47
Testosterone Approved, Experimental, Investigational Phase 4 481-30-1, 58-22-0 6013 10204
48
Ziprasidone Approved Phase 4 146939-27-7 60854
49
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
50
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994

Interventional clinical trials:

(show top 50) (show all 1108)
# Name Status NCT ID Phase Drugs
1 Rosiglitazone Therapy In The Prevention Of Coronary Artery Disease In Patients With Impaired Glucose Tolerance Unknown status NCT00733174 Phase 4 Rosiglitazone;Placebo
2 Antiatherogenic and Antimetabolic Effect of Curcumin Therapy in the Prevention and Delay of Type 2 Diabetic in Patients With Impaired Glucose Tolerance and Insulin Resistance Unknown status NCT01052025 Phase 4 Curcumin
3 Multicenter Trial on Clinical Utility of Acarbose in Patients With Ischemic Heart Disease Accompanied by Abnormal Glucose Regulation Unknown status NCT00858676 Phase 4 acarbose
4 Intensity of Exercise and Glucose Metabolism Unknown status NCT01649219 Phase 4
5 Effect of Saxagliptin on Body Fat , Glucose and Beta Cell Function in Patients With Newly Diagnosed Pre-Diabetes Mellitus and Obesity Unknown status NCT01960205 Phase 4 Saxagliptin;saxagliptin;metformin
6 Acthar as Rescue Therapy for Transplant Glomerulopathy in Kidney Transplant Recipients Unknown status NCT02057523 Phase 4 Acthar
7 Effects of Growth Hormone on Body Fat Distribution, Insulin Action and Cardiovascular Risk Factors in Middle-Aged Men With Metabolic Syndrome Unknown status NCT00307411 Phase 4 Growth hormone
8 The Impacts of Vitamin D Supplementation on Glucose Metabolism in Chinese Women With Vitamin D Deficiency and Former Gestational Diabetes Mellitus:A Randomised Control Trial Unknown status NCT03138616 Phase 4 vitamin D
9 evAluation of Glycemic RangE During acutE Coronary syndroME in Nondiabetic paTients Unknown status NCT02932592 Phase 4
10 Healthy Heart Study: Can Insulin Glargine Improve Myocardial Function in Patients With Type 2 Diabetes and Coronary Artery Disease? A Prospective, Randomized, Controlled Clinical Study With Blinded Analysis of Ultrasound Data Unknown status NCT01035528 Phase 4 insulin glargine;metformin
11 Comparison of Single and Combination Diuretics in Low-Renin Hypertension Unknown status NCT02351973 Phase 4 Hydrochlorthiazide;Amiloride;Hydrochlorthiazide and Amiloride
12 Effect of Rubus Occidentalis Extract on Plasma Glucose Levels in Subject With Prediabetes; A Proof-of-concept, Randomized, Double-blind, Parallel-group Placebo-controlled Study Completed NCT01964703 Phase 4 Rubus occidentalis extract
13 Effects of Physical Exercise Versus Rosiglitazone on Endothelial Function in Coronary Artery Disease Patients With Prediabetes Completed NCT00675740 Phase 4 rosiglitazone
14 Efficacy and Safety of Nateglinide Treatment in Renal Treatment Recipients With Post Transplant Diabetes Mellitus or Impaired Glucose Tolerance Completed NCT00319189 Phase 4 Nateglinide
15 Exercise in Elderly Individuals With Impaired Glucose Tolerance: Beneficial for Vasculature and Neurons? Completed NCT01219231 Phase 4
16 The Chronic and Acute Postprandial Vascular Effects of Exenatide vs. Metformin in Abdominally Obese Patients With Impaired Glucose Tolerance Completed NCT00546728 Phase 4 Exenatide;Metformin
17 Japan Prevention Trial of Diabetes by Pitavastatin in Patients With Impaired Glucose Tolerance (J-PREDICT) Completed NCT00301392 Phase 4 Life style interventions plus concomitant use of pitavastatin.
18 A Single Center, Open Label, Single Arm Trial To Evaluate The Effect Of Twenty Four Weeks Of Treatment With 80 Mg To 320 Mg Valsartan On Insulin Sensitivity In Subjects With Impaired Glucose Tolerance (Igt) Completed NCT00241072 Phase 4 valsartan
19 Effect of Exenatide on Brain Glucose Uptake in Relations to Pancreatic, Adipose Tissue, and Hepatic Function Completed NCT01588418 Phase 4 Exenatide;Placebo
20 The Effect of Sitagliptin Treatment on Glucose Metabolism and Endothelial Function in Renal Transplant Recipients - JANUVIA-08 Completed NCT00740363 Phase 4 sitagliptin;placebo
21 Effects of Insulin Sensitizers in Subjects With Impaired Glucose Tolerance Completed NCT00108615 Phase 4 Metformin;Pioglitazone;Metformin;Pioglitazone
22 Dipeptidyl Peptidase-4 (DPP-4) Inhibitor Sitagliptin Improved Beta Cell Function and Prevented a Conversion Rate to Impaired Glucose Tolerance IGT and Type 2 Diabetes T2D in Metformin Intolerant Obese Women With Polycystic Ovary Syndrome PCOS Completed NCT03122041 Phase 4 Sitagliptin
23 Blood Pressure and Metabolic Effects of Nebivolol Compared With Hydrochlorothiazide and Placebo in Hypertensive Patients With Impaired Glucose Tolerance or Impaired Fasting Glucose Completed NCT00673790 Phase 4 Nebivolol;HCTZ;Placebo
24 Postmarketing Clinical Study on AO-128 Completed NCT02287402 Phase 4 AO-128
25 Effects of GH and Pioglitazone in Viscerally Obese Adults With IGT Completed NCT00352287 Phase 4 Recombinant human growth hormone; pioglitazone
26 A Long-term, Multicentre, Double-blind, Randomised Parallel-group Trial to Determine Whether Reducing Post-prandial Glycaemia Can Reduce Cardiovascular-related Morbidity and Mortality in Patients With Established Coronary Heart Disease or Acute Coronary Syndrome Who Have Impaired Glucose Tolerance Completed NCT00829660 Phase 4 Acarbose;Matching Placebo
27 Effect of Dapagliflozin on Insulin Secretion and Insulin Sensitivity in Patients With Prediabetes Completed NCT02700334 Phase 4 Dapagliflozin;Placebo
28 Effect of Linagliptin + Metformin vs Metformin Alone on the Role of Pancreatic Islet Function, Insulin Resistance and Markers of Cardiovascular Risk in Patients With Prediabetes: Randomized Clinical Trial Completed NCT03004612 Phase 4 Metformin
29 A Randomized Pilot Study Evaluating Combination Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Plus Metformin Compared to Metformin Monotherapy and Placebo on Metabolic Abnormalities in Women With a Recent History of GDM Completed NCT01856907 Phase 4 Sitagliptin-Metformin;Metformin;Placebo pill
30 Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH) Completed NCT00227110 Phase 4 Pioglitazone;Placebo
31 Metabolic Effects of Antihypertensive Drugs Completed NCT00887510 Phase 4 Hydrochlorothiazide;Trandolapril
32 The Effect of Exenatide on Body Weight, Energy Expenditure and Hunger in Obese Women Without Diabetes Mellitus Completed NCT00456885 Phase 4 exenatide;Placebo
33 The Role of Incretins in the Pathogenesis of Fasting and Postprandial Glucose Metabolism in People With Impaired Fasting Glucose Completed NCT00364377 Phase 4 Sitagliptin
34 Telmisartan vs. Losartan in Hypertensive Patients With Impaired Glucose Tolerance: A Comparison of Their Antihypertensive, Metabolic, and Vascular Effects Completed NCT00407862 Phase 4 Telmisartan 80 mg;Losartan 50 mg
35 Effect of Pioglitazone With and Without Exenatide on Body Weight, Fat Topography, Beta Cell Function, and Glycemic Control in Type 2 Diabetic Patients Completed NCT00845182 Phase 4 Pioglitazone;Exenatide;Pioglitazone and Exenatide
36 Long-term Role of Pioglitazone in Non-Alcoholic Fatty Liver Disease (NAFLD) in Type 2 Diabetes Mellitus (T2DM). Completed NCT00994682 Phase 4 Pioglitazone study drug;Placebo;Pioglitazone Open Label
37 Effects of Vitamin D on Beta Cell Function and Insulin Sensitivity in Pre-diabetes and Diabetes Mellitus Type 2 - EVIDENS Completed NCT01497132 Phase 4 Vitamin D3;Placebo
38 Effects of Exenatide on Postprandial Hyperlipidemia and Inflammation Completed NCT00974272 Phase 4 Exenatide
39 The Assessment of the Effect of Metformin and Its Serum Concentration on the Concentration of Substances Associated With the Production of Nitric Oxide in Patients With Impaired Carbohydrate Metabolism Completed NCT03398356 Phase 4 Metformin
40 Quantitative Assessment and Comparison of Metabolic Changes in Non-psychotic Adults Taking the Antipsychotic Medications Fanapt (Iloperidone) or Zyprexa (Olanzapine) or Placebo Completed NCT01920802 Phase 4 olanzapine;iloperidone;Placebo
41 Phase IV Study Evaluating the Effect of Sitagliptin (Januvia™) on Beta-cell Function in Patients With Acute Myocardial Infarction or Unstable Angina Pectoris and Newly Detected Impaired Glucose Tolerance or Type 2 Diabetes. Completed NCT00627744 Phase 4 Sitagliptin
42 One-Year Glargine-Treatment Can Ameliorate Clinical Features in Cystic Fibrosis Children and Adolescents With Glucose Derangements Completed NCT00483769 Phase 4 Glargine
43 Treatment With Sitagliptin Phosphate in Patients With Reactive Hypoglycemia Secondary to Dysinsulinism. A Controlled, Randomized, Double-blind, Clinical Trial Completed NCT00847080 Phase 4 Sitagliptin phosphate;Placebo
44 Mechanisms of Action of Hydroxychloroquine in Reducing Risk of Type 2 Diabetes Completed NCT01326533 Phase 4 hydroxychloroquine
45 Effect of Acarbose on Postprandial Lipoprotein Levels in Glucose Intolerant Patients Completed NCT02355509 Phase 4 Acarbose;Placebo
46 Oral Cholecalciferol in Prevention of Type 2 DM in Prediabetic Population With Vitamin D Insufficiency Completed NCT01436916 Phase 4 oral cholecalciferol + life style counselling;placebo + life style counselling
47 Oral Contraceptives, Insulin Resistance and Cardiovascular Risk Profile in Pre-Menopausal Women Completed NCT01475513 Phase 4 Ortho Cyclen®
48 Effects of Cyclosporine A on Pancreatic Insulin Secretion Completed NCT00139035 Phase 4 cyclosporine A
49 Randomised, Double-Arm, Controlled, Open-Label Study Comparing Calcineurin Inhibitor-Free Immunosuppression (Zenapax®, CellCept® and Prednisolone) and Cyclosporine A Based Immunosuppression (Sandimmun Neoral®, CellCept® and Prednisolone) on the Outcome of Renal Function and Acute Rejection in 0 DR Mis-Matched Renal Allograft Recipients Completed NCT00138970 Phase 4 Zenapax®, CellCept® and prednisolone;Sandimmun Neoral®, CellCept® and prednisolone
50 Effect of Anthocyanins on Metabolic Profiles in Subjects With Pre-diabetes: A Randomized, Double-blind, Placebo-controlled Study Completed NCT02689765 Phase 4

Search NIH Clinical Center for Glucose Intolerance

Inferred drug relations via UMLS 72 / NDF-RT 51 :


glucomannan

Cochrane evidence based reviews: glucose intolerance

Genetic Tests for Glucose Intolerance

Genetic tests related to Glucose Intolerance:

# Genetic test Affiliating Genes
1 Glucose Intolerance 29

Anatomical Context for Glucose Intolerance

MalaCards organs/tissues related to Glucose Intolerance:

41
Liver, Ovary, Testes, Heart, Endothelial, Skeletal Muscle, Kidney

Publications for Glucose Intolerance

Articles related to Glucose Intolerance:

(show top 50) (show all 9961)
# Title Authors PMID Year
1
Structure guided design of 5-arylindazole glucocorticoid receptor agonists and antagonists. 9 38
20469868 2010
2
Serum 25-hydroxy vitamin d and insulin resistance, metabolic syndrome, and glucose intolerance among Arab Americans. 9 38
20332348 2010
3
Adiponectin is independently associated with apolipoprotein B to A-1 ratio in Koreans. 9 38
19914667 2010
4
Disruption of the dopamine d2 receptor impairs insulin secretion and causes glucose intolerance. 9 38
20147524 2010
5
Obesity and type 2 diabetes: slow down!--Can metabolic deceleration protect the islet beta cell from excess nutrient-induced damage? 9 38
19815054 2010
6
Leptin and the metabolic syndrome in patients with myotonic dystrophy type 1. 9 38
19804472 2010
7
Adiponectin and carotid intimal medial thickness in subjects with and without glucose intolerance (CURES-82). 9 38
20105040 2010
8
Adiponectin in insulin resistance: lessons from translational research. 9 38
19906806 2010
9
Retinol-binding protein 4 levels in obese children and adolescents with glucose intolerance. 9 38
20389103 2010
10
Acromegaly pathogenesis and treatment. 9 38
19884662 2009
11
Human serum metabonomic analysis reveals progression axes for glucose intolerance and insulin resistance statuses. 9 38
19697961 2009
12
The prevalence of abnormal liver enzymes and metabolic syndrome in obese adolescent females with polycystic ovary syndrome. 9 38
19576817 2009
13
The prevalence and risk factors for glucose intolerance in young Korean women with polycystic ovary syndrome. 9 38
19688613 2009
14
Inflammatory mediators in morbidly obese subjects: associations with glucose abnormalities and changes after oral glucose. 9 38
19542241 2009
15
Evidence for association between polycystic ovary syndrome (PCOS) and TCF7L2 and glucose intolerance in women with PCOS and TCF7L2. 9 38
19351735 2009
16
Cassia cinnamon for the attenuation of glucose intolerance and insulin resistance resulting from sleep loss. 9 38
19627193 2009
17
Pre-gravid physical activity and reduced risk of glucose intolerance in pregnancy: the role of insulin sensitivity. 9 38
18793347 2009
18
Visceral obesity is associated with the metabolic syndrome and elevated plasma retinol binding protein-4 level in obstructive sleep apnea syndrome. 9 38
19003725 2009
19
Early atherosclerosis and vascular inflammation in mice with diet-induced type 2 diabetes. 9 38
19260948 2009
20
Impact of adiponectin and ghrelin on incident glucose intolerance and on weight change. 9 38
18624998 2009
21
Association between insulin resistance, glucose intolerance, and hypertension in pregnancy. 9 38
18847384 2009
22
A cross-sectional study for glucose intolerance of myotonic dystrophy. 9 38
18834994 2009
23
Prevalence of metabolic syndrome and related characteristics in obese adolescents with and without polycystic ovary syndrome. 9 38
18812482 2008
24
[Polymorphism of glucose intolerance and insulin resistance susceptibility genes in oncological patients]. 9 38
19140314 2008
25
Ketogenic diet-fed rats have increased fat mass and phosphoenolpyruvate carboxykinase activity. 9 38
18655006 2008
26
Impaired glucose tolerance and insulin resistance are associated with increased adipose 11beta-hydroxysteroid dehydrogenase type 1 expression and elevated hepatic 5alpha-reductase activity. 9 38
18633104 2008
27
Associations between sex hormone binding globulin and metabolic syndrome parameters in premenopausal obese women. 9 38
19008614 2008
28
Impact of obstructive sleep apnea on insulin resistance and glucose tolerance in women with polycystic ovary syndrome. 9 38
18647805 2008
29
Hypothalamic IKKbeta/NF-kappaB and ER stress link overnutrition to energy imbalance and obesity. 9 38
18854155 2008
30
Effects of telmisartan on adiponectin levels and body weight in hypertensive patients with glucose intolerance. 9 38
18803955 2008
31
A cross-sectional study of the association between persistent organic pollutants and glucose intolerance among Greenland Inuit. 9 38
18560802 2008
32
High plasma retinol binding protein-4 and low plasma adiponectin concentrations are associated with severity of glucose intolerance in women with previous gestational diabetes mellitus. 9 38
18492757 2008
33
Effect of low-dose oral contraceptives on metabolic risk factors in African-American women. 9 38
18334585 2008
34
Chromium alleviates glucose intolerance, insulin resistance, and hepatic ER stress in obese mice. 9 38
18388893 2008
35
Circulating and cellular adiponectin in polycystic ovary syndrome: relationship to glucose tolerance and insulin action. 9 38
17706206 2008
36
Influence of the ACE gene insertion/deletion polymorphism on insulin sensitivity and impaired glucose tolerance in healthy subjects. 9 38
18235053 2008
37
Insulin-like growth factor-(IGF)-axis, inflammation, and glucose intolerance among older adults. 9 38
17904401 2008
38
Insulin and its role in chronic kidney disease. 9 38
17929061 2008
39
Adiponectin and its role in cardiovascular diseases. 9 38
18336252 2008
40
Altered expression of glucagon-like peptide-1 and dipeptidyl peptidase IV in patients with HCV-related glucose intolerance. 9 38
17944883 2008
41
How many components for the metabolic syndrome? Results of exploratory factor analysis in the FIBAR study. 9 38
17387006 2007
42
Suppressive effects of diacylglycerol oil on postprandial hyperlipidemia in insulin resistance and glucose intolerance. 9 38
17125771 2007
43
Glucocorticoids and cardiovascular disease. 9 38
17984234 2007
44
Fetal determinants of type 2 diabetes. 9 38
17691930 2007
45
Muscle GLUT4 in cirrhosis. 9 38
17448565 2007
46
Resistin, acute coronary syndrome and prognosis results from the AtheroGene study. 9 38
16814296 2007
47
[Effect of progressive insulin resistance on the correlation of glucose metabolism and bone status]. 9 38
17561482 2007
48
Normal adiponectin levels despite abnormal glucose tolerance (or diabetes) and inflammation in adult patients with cystic fibrosis. 9 38
17418606 2007
49
Early-phase insulin secretion is disturbed in obese subjects with glucose intolerance. 9 38
17512320 2007
50
Protease inhibitor-based antiretroviral therapy and glucose tolerance in pregnancy: AIDS Clinical Trials Group A5084. 9 38
17403409 2007

Variations for Glucose Intolerance

ClinVar genetic disease variations for Glucose Intolerance:

6
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 MT-TL1 NC_012920.1: m.3243A> G single nucleotide variant Pathogenic rs199474657 MT:3243-3243 MT:3243-3243

Expression for Glucose Intolerance

Search GEO for disease gene expression data for Glucose Intolerance.

Pathways for Glucose Intolerance

Pathways related to Glucose Intolerance according to GeneCards Suite gene sharing:

(show all 33)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.51 LEPR LEP IRS1 INSR INS GCG
2
Show member pathways
12.85 SLC2A4 IRS1 INSR INS IGF1 GCK
3
Show member pathways
12.65 SLC2A4 RETN RBP4 LEP IRS1 INSR
4 12.47 SLC2A4 IRS1 INSR INS IGFBP1 GCG
5
Show member pathways
12.45 LEPR LEP IRS1 INS GCK
6
Show member pathways
12.44 SLC2A4 IRS1 INSR INS
7
Show member pathways
12.42 IRS1 INSR INS IGF1
8
Show member pathways
12.27 IRS1 INSR IGF1 ADRB3
9
Show member pathways
12.19 LEP INS IGF1 GHRL GCG DPP4
10
Show member pathways
12.18 SLC2A4 LEP IRS1 INSR INS
11
Show member pathways
12.17 SLC2A4 LEPR LEP IRS1 INSR INS
12
Show member pathways
12.11 IRS1 INSR INS IGF1 ADIPOQ
13
Show member pathways
12.03 SLC2A4 IRS1 INSR INS IGF1
14
Show member pathways
11.92 SLC2A4 IRS1 INSR INS
15 11.86 INSR INS IGF1
16
Show member pathways
11.72 SLC2A4 IRS1 INSR INS GCK ADIPOQ
17 11.64 SLC2A4 LEPR LEP IRS1 ADIPOQ
18 11.63 IRS1 INSR INS
19 11.62 LEP IGFBP1 GCK
20 11.57 IRS1 INSR INS ADRB3
21
Show member pathways
11.55 LEP GCG DPP4
22 11.53 SLC2A4 LEPR LEP IRS1
23 11.49 INSR INS IGF1
24 11.44 INS IGFBP1 GCK
25 11.42 IRS1 INSR INS
26 11.42 LEPR LEP IRS1 INSR INS
27 11.35 IRS1 INSR INS IGF1
28 11.29 SLC2A4 RETN LEP IRS1 INS IGF1
29
Show member pathways
11.24 LEPR LEP CRP
30 11.22 SLC2A4 INSR INS
31
Show member pathways
10.95 SLC2A4 IRS1 INSR
32 10.94 SLC2A4 INS GPT
33 10.7 SLC2A4 LEP IRS1 INSR ADIPOQ

GO Terms for Glucose Intolerance

Cellular components related to Glucose Intolerance according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.7 RETN RBP4 LEP INS IGFBP1 IGF1
2 endoplasmic reticulum lumen GO:0005788 9.56 INS IGFBP1 GHRL GCG
3 secretory granule lumen GO:0034774 9.5 INS GHRL GCG
4 extracellular region GO:0005576 9.44 SHBG RETN RBP4 LEPR LEP INS
5 insulin receptor complex GO:0005899 9.16 IRS1 INSR

Biological processes related to Glucose Intolerance according to GeneCards Suite gene sharing:

(show all 40)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.98 LEP IGF1 GHRL GCG
2 carbohydrate metabolic process GO:0005975 9.93 SLC2A4 INSR INS GCK ADRB3
3 positive regulation of protein kinase B signaling GO:0051897 9.91 LEP IRS1 INSR INS
4 response to ethanol GO:0045471 9.87 SLC2A4 RBP4 LEP ADIPOQ
5 response to insulin GO:0032868 9.83 RETN LEP IRS1
6 positive regulation of MAPK cascade GO:0043410 9.83 LEP INSR INS IGF1 ADRB3
7 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.82 LEP INS IGF1
8 insulin receptor signaling pathway GO:0008286 9.81 IRS1 INSR INS IGFBP1
9 response to nutrient levels GO:0031667 9.8 LEP GHRL ADIPOQ
10 positive regulation of cold-induced thermogenesis GO:0120162 9.8 LEPR LEP GHRL ADRB3 ADIPOQ
11 regulation of insulin secretion GO:0050796 9.78 LEP GCK GCG DPP4
12 positive regulation of insulin secretion GO:0032024 9.77 RBP4 GHRL GCK
13 cellular response to insulin stimulus GO:0032869 9.77 SLC2A4 IRS1 INSR GCK ADIPOQ
14 activation of protein kinase B activity GO:0032148 9.75 INSR INS IGF1
15 positive regulation of mitotic nuclear division GO:0045840 9.73 INSR INS IGF1
16 glucose metabolic process GO:0006006 9.72 LEP INS GHRL GCK ADIPOQ
17 positive regulation of glycolytic process GO:0045821 9.7 INSR INS IGF1
18 positive regulation of cellular protein metabolic process GO:0032270 9.68 INS ADIPOQ
19 insulin-like growth factor receptor signaling pathway GO:0048009 9.68 IRS1 IGF1
20 negative regulation of macrophage derived foam cell differentiation GO:0010745 9.67 CRP ADIPOQ
21 sexual reproduction GO:0019953 9.67 LEPR LEP
22 neuron projection maintenance GO:1990535 9.67 INSR INS
23 positive regulation of insulin receptor signaling pathway GO:0046628 9.67 LEP IRS1 INS
24 negative regulation of blood vessel diameter GO:0097756 9.66 INS CRP
25 cellular response to leptin stimulus GO:0044320 9.66 LEP GCK
26 adult feeding behavior GO:0008343 9.65 LEP GHRL
27 negative regulation of lipid storage GO:0010888 9.64 LEP CRP
28 leptin-mediated signaling pathway GO:0033210 9.64 LEPR LEP
29 negative regulation of feeding behavior GO:2000252 9.63 RETN INS
30 energy reserve metabolic process GO:0006112 9.63 LEPR LEP ADRB3
31 regulation of bone remodeling GO:0046850 9.62 LEPR LEP
32 positive regulation of respiratory burst GO:0060267 9.62 INSR INS
33 positive regulation of developmental growth GO:0048639 9.61 LEP INSR
34 bone mineralization involved in bone maturation GO:0035630 9.6 LEP IGF1
35 negative regulation of gluconeogenesis GO:0045721 9.56 LEPR INS GCK ADIPOQ
36 bone growth GO:0098868 9.55 LEPR LEP
37 positive regulation of glucose import GO:0046326 9.55 IRS1 INSR INS IGF1 ADIPOQ
38 positive regulation of glycogen biosynthetic process GO:0045725 9.35 IRS1 INSR INS IGF1 GCK
39 glucose homeostasis GO:0042593 9.28 SLC2A4 RBP4 LEPR LEP IRS1 INSR
40 positive regulation of cell proliferation GO:0008284 10.06 LEP IRS1 INSR INS IGF1 DPP4

Molecular functions related to Glucose Intolerance according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 9.65 LEP IGFBP1 GCG DPP4 ADIPOQ
2 insulin-like growth factor I binding GO:0031994 9.37 INSR IGFBP1
3 insulin receptor binding GO:0005158 9.33 IRS1 INS IGF1
4 insulin-like growth factor II binding GO:0031995 9.32 INSR IGFBP1
5 insulin-like growth factor receptor binding GO:0005159 9.26 IRS1 INSR INS IGF1
6 hormone activity GO:0005179 9.17 RETN LEP INS IGF1 GHRL GCG

Sources for Glucose Intolerance

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49